Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K
PloS one · 89 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Japan Society for the Promotion of Science
- Subvenciones
- Japan Society for the Promotion of Science (24701037)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2014-07-14 · PLoS One · vol. 9 · número 7 · pág. e101902
- Editorial
- Public Library of Science
- Citado
- 130 citas · más que el 98% de estudios similares · 8.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 32 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Chemotherapy-induced organ toxicity mitigation · Magnesium in Health and Disease · Silymarin and Mushroom Poisoning
- Palabras clave
- Nephrotoxicity, Medicine, Hypomagnesemia, Creatinine, Cisplatin, Common Terminology Criteria for Adverse Events, Toxicity, Internal medicine, Renal function, Urology, Chemotherapy, Acute kidney injury, Adverse effect, Gastroenterology, Pharmacology, Magnesium, Chemistry
- MeSH
- humans, neoplasms, kidney diseases, cisplatin, magnesium, creatinine, multivariate analysis, odds ratio, risk factors, retrospective studies, dna mutational analysis, dietary supplements
16 autores
- Yasuhiro Kidera🇯🇵Kindai University
- Hisato Kawakami🇯🇵 · autor de correspondenciaKindai University
- Tsutomu Sakiyama🇯🇵Kindai University
- Kunio Okamoto🇯🇵Kindai University
- Kaoru Tanaka🇯🇵Kindai University
- Masayuki Takeda🇯🇵Kindai University
- Hiroyasu Kaneda🇯🇵Kindai University
- Shinichi Nishina🇯🇵Kindai University
- Junji Tsurutani🇯🇵Kindai University
- Kimiko Fujiwara🇯🇵Kindai University
- Morihiro Nomura🇯🇵Kindai University
- Yuzuru Yamazoe🇯🇵Kindai University
- Yasutaka Chiba🇯🇵Kindai University
- Shozo Nishida🇯🇵Kindai University
- Takao Tamura🇯🇵Kindai University
- Kazuhiko Nakagawa🇯🇵Kindai University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors for cisplatin-induced nephrotoxicity as well as the potential impact of intravenous magnesium supplementation on such toxicity.
Patients and methods
We reviewed clinical data for 401 patients who underwent chemotherapy including a high dose (≥60 mg/m2) of cisplatin in the first-line setting. Nephrotoxicity was defined as an increase in the serum creatinine concentration of at least grade 2 during the first course of cisplatin chemotherapy, as assessed on the basis of National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The severity of nephrotoxicity was evaluated on the basis of the mean change in the serum creatinine level. Magnesium was administered intravenously to 67 patients (17%).
Results
Cisplatin-induced nephrotoxicity was observed in 127 patients (32%). Multivariable analysis revealed that an Eastern Cooperative Oncology Group performance status of 2 (risk ratio, 1.876; P = 0.004) and the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) (risk ratio, 1.357; P = 0.047) were significantly associated with an increased risk for cisplatin nephrotoxicity, whereas intravenous magnesium supplementation was associated with a significantly reduced risk for such toxicity (risk ratio, 0.175; P = 0.0004). The development of hypomagnesemia during cisplatin treatment was significantly associated with a greater increase in serum creatinine level (P = 0.0025). Magnesium supplementation therapy was also associated with a significantly reduced severity of renal toxicity (P = 0.012).
Conclusions
A relatively poor performance status and the regular use of NSAIDs were significantly associated with cisplatin-induced nephrotoxicity, although the latter association was marginal. Our findings also suggest that the ability of magnesium supplementation to protect against the renal toxicity of cisplatin warrants further investigation in a prospective trial.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.